Home > Name List By a > azane

CAS No 181630-15-9 , azane

  • Name: azane
  • Synonyms: (SP-4-3)-Amminedichloro(2-methylpyridine)platinium; ZD0473;181630-15-9;azane;2-methylpyridine; AC1L42P3;platinum(2+); AMD 473; Picoplatin [INN:BAN];dichloride; LS-184068; ZD 0473;
  • CAS Registry Number:
  • Transport: 2811
  • Flash Point: 26.1°C
  • Boiling Point: 127.5°Cat760mmHg
  • Density: g/cm3
  • Safety Statements: RIDADR 2811HazardClass 6.1(a)PackingGroup II
  • Flash Point: 26.1°C
  • Molecular Weight: 376.147
  • InchiKey: IIMIOEBMYPRQGU-UHFFFAOYSA-L
  • InChI: InChI=1S/C6H7N.2ClH.H3N.Pt/c1-6-4-2-3-5-7-6;;;;/h2-5H,
    1H3;2*1H;1H3;/q;;;;+2/p-2
  • Molecular Formula: C6H10Cl2N2Pt
  • Molecular Structure:CAS No:181630-15-9 azane

Related products

Search by region :

Select to

181630-15-9 ZD0473

  • China Nanjing Chemlin Chemical Industry Co.,Ltd. [Manufacturer]
  • Tel: +86 25 8369-7070/ +86 138 51816776 (Mobile)
  • Fax: +86 25 8345-3275
  • Address: Rm.902 Longyin Plaza,
    No. 217 Zhongshan Rd.
    (N)Nanjing 210009,China null,nullChina
Contact Supplier

181630-15-9 PICOPLATIN AMD-473; JM-473; NX-473; ZD-473

  • United States LC Laboratories [Manufacturer]
  • Tel: 781-937-0777
  • Fax: 781-938-5420
  • Address: LC Laboratories
    165 New Boston Street
    Woburn, MA 01801 USA null,nullUnited States
Contact Supplier

Select to

1/1
References of azane
Title: Picoplatin
CAS Registry Number: 181630-15-9
CAS Name: (SP-4-3)-Amminedichloro(2-methylpyridine)platinum
Synonyms: cis-amminedichloro(2-methylpyridine)platinum(II)
Manufacturers' Codes: AMD-473; JM-473; NX-473; ZD-473
Molecular Formula: C6H10Cl2N2Pt
Molecular Weight: 376.15
Percent Composition: C 19.16%, H 2.68%, Cl 18.85%, N 7.45%, Pt 51.86%
Literature References: Third generation, sterically hindered Pt-complex that exhibits reduced reactivity with sulfur ligands such as glutathione, q.v.; designed to overcome acquired Pt-chemotherapy resistance. Prepn: B. A. Murrer, EP 727430 (1996 to AnorMED; Inst. of Cancer Research); idem, US 5665771 (1997 to Johnson Matthey). Pharmacology and pharmacokinetics: F. I. Raynaud et al., Clin. Cancer Res. 3, 2063 (1997). Cytotoxicity and DNA binding activity: J. Holford et al., Anti-Cancer Drug Design 13, 1 (1998). In vitro circumvention of cisplatin resistance: idem, et al,. Br. J. Cancer 77, 366 (1998); of radiosensitizing activity: G. P. Raaphorst et al., Anticancer Res. 24, 613 (2004). LC/MS determn in plasma: T. Oe et al., Anal. Chem. 74, 591 (2002); in urine: eidem, J. Chromatogr. B 792, 217 (2003). Series of articles on clinical evaluations: Eur. J. Cancer 38, Suppl. S1-S31 (2002). Review of early development: L. R. Kelland et al., J. Inorg. Biochem. 77, 111-115 (1999); and therapeutic potential: M. P. Hay, Curr. Opin. Invest. Drugs 1, 263-266 (2000).
Properties: Pale yellow solid. Sensitive to light. uv max (0.15M sodium chloride): 268 nm. A250/A268 = 0.62. LD50 in mice (mg/kg): 43 i.p., 560 orally (Murrer).
Absorption maximum: uv max (0.15M sodium chloride): 268 nm
Toxicity data: LD50 in mice (mg/kg): 43 i.p., 560 orally (Murrer)
Therap-Cat: Antineoplastic.
Keywords: Antineoplastic; Platinum Complexes.